tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Uveitis D014605 14 associated lipids
Urticaria D014581 13 associated lipids
Urination Disorders D014555 9 associated lipids
Urinary Tract Infections D014552 11 associated lipids
Uremia D014511 33 associated lipids
Ulcer D014456 16 associated lipids
Tuberous Sclerosis D014402 2 associated lipids
Trypanosomiasis D014352 5 associated lipids
Trichomonas Vaginitis D014247 2 associated lipids
Trichomonas Infections D014245 3 associated lipids
Tremor D014202 15 associated lipids
Translocation, Genetic D014178 20 associated lipids
Toxocariasis D014120 3 associated lipids
Tongue Diseases D014060 2 associated lipids
Tinea Capitis D014006 1 associated lipids
Tinea D014005 5 associated lipids
Thyroiditis, Autoimmune D013967 9 associated lipids
Thyroid Diseases D013959 8 associated lipids
Thymus Neoplasms D013953 15 associated lipids
Thrombosis D013927 49 associated lipids
Thrombophlebitis D013924 6 associated lipids
Thrombocytopenia D013921 15 associated lipids
Thinness D013851 11 associated lipids
Testicular Diseases D013733 15 associated lipids
Telangiectasis D013684 2 associated lipids
Tachycardia D013610 7 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Subarachnoid Hemorrhage D013345 17 associated lipids
Stomatitis D013280 14 associated lipids
Stomach Ulcer D013276 75 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Sleep Wake Disorders D012893 7 associated lipids
Skin Neoplasms D012878 12 associated lipids
Skin Diseases, Vesiculobullous D012872 5 associated lipids
Sinusitis D012852 9 associated lipids
Shock, Septic D012772 11 associated lipids
Shock D012769 11 associated lipids
Seizures D012640 87 associated lipids
Dermatitis, Seborrheic D012628 10 associated lipids
Sclerosis D012598 5 associated lipids
Scalp Dermatoses D012536 11 associated lipids
Osteosarcoma D012516 50 associated lipids
Sarcoma, Kaposi D012514 6 associated lipids
Sarcoidosis D012507 13 associated lipids
Rupture D012421 2 associated lipids
Rotavirus Infections D012400 1 associated lipids
Rosacea D012393 13 associated lipids
Rheumatoid Nodule D012218 1 associated lipids
Rhabdomyolysis D012206 9 associated lipids
Retinoblastoma D012175 12 associated lipids
Respiratory Tract Neoplasms D012142 2 associated lipids
Respiratory Insufficiency D012131 10 associated lipids
Respiration Disorders D012120 5 associated lipids
Reflex Sympathetic Dystrophy D012019 4 associated lipids
Red-Cell Aplasia, Pure D012010 4 associated lipids
Rectal Fistula D012003 2 associated lipids
Rectal Diseases D012002 1 associated lipids
Purpura, Thrombotic Thrombocytopenic D011697 6 associated lipids
Pulmonary Veno-Occlusive Disease D011668 1 associated lipids
Pterygium D011625 3 associated lipids
Psychoses, Substance-Induced D011605 7 associated lipids
Psoriasis D011565 47 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Pseudohypoaldosteronism D011546 1 associated lipids
Pruritus Vulvae D011539 1 associated lipids
Pruritus Ani D011538 2 associated lipids
Prurigo D011536 4 associated lipids
Proteinuria D011507 30 associated lipids
Priapism D011317 1 associated lipids
Pregnancy Complications D011248 19 associated lipids
Precancerous Conditions D011230 48 associated lipids
Poxviridae Infections D011213 1 associated lipids
Postoperative Complications D011183 5 associated lipids
Polyneuropathies D011115 3 associated lipids
Pityriasis D010915 3 associated lipids
Pharyngitis D010612 2 associated lipids
Peritoneal Neoplasms D010534 16 associated lipids
Peripheral Nervous System Diseases D010523 33 associated lipids
Periodontal Pocket D010514 9 associated lipids
Pericarditis D010493 6 associated lipids
Perceptual Disorders D010468 3 associated lipids
Peptic Ulcer Perforation D010439 3 associated lipids
Peptic Ulcer D010437 19 associated lipids
Pemphigus D010392 3 associated lipids
Pemphigoid, Bullous D010391 8 associated lipids
Pemphigoid, Benign Mucous Membrane D010390 4 associated lipids
Parotitis D010309 4 associated lipids
Paronychia D010304 3 associated lipids
Parkinson Disease D010300 53 associated lipids
Paresis D010291 2 associated lipids
Paraproteinemias D010265 2 associated lipids
Pancytopenia D010198 6 associated lipids
Pancreatic Fistula D010185 2 associated lipids
Pain, Intractable D010148 4 associated lipids
Pain D010146 64 associated lipids
Ovarian Cysts D010048 4 associated lipids
Osteoporosis D010024 12 associated lipids
Osteonecrosis D010020 5 associated lipids
Osteomalacia D010018 5 associated lipids
Osteochondrodysplasias D010009 3 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Thomson AW et al. FK 506, cardiac transplantation, and graft-vessel disease. 1992 Lancet pmid:1370563
First MR Transplantation in the nineties. 1992 Transplantation pmid:1370734
Naito M et al. Reversal of multidrug resistance by an immunosuppressive agent FK-506. 1992 Cancer Chemother. Pharmacol. pmid:1370765
Yem AW et al. The Hsp56 component of steroid receptor complexes binds to immobilized FK506 and shows homology to FKBP-12 and FKBP-13. 1992 J. Biol. Chem. pmid:1371107
Park ST et al. PPIase catalysis by human FK506-binding protein proceeds through a conformational twist mechanism. 1992 J. Biol. Chem. pmid:1371117
Bishop DK and Li W Cyclosporin A and FK506 mediate differential effects on T cell activation in vivo. 1992 J. Immunol. pmid:1371128
Hatfield SM and Roehm NW Cyclosporine and FK506 inhibition of murine mast cell cytokine production. 1992 J. Pharmacol. Exp. Ther. pmid:1371158
Johnson MC et al. QT prolongation and Torsades de Pointes after administration of FK506. 1992 Transplantation pmid:1373538
Kim YI et al. Stimulation of liver regeneration by pretreatment with azathioprine as well as cyclosporine and FK506. 1992 Transplantation pmid:1373539
Carobbi A et al. Synergism of splenectomy and immunosuppressive drugs in prolongation of cardiac xenograft survival. 1992 Transplant. Proc. pmid:1373543
Ueno M et al. Immunosuppressive effect in combination therapy of cyclosporine A, FK 506, and 15-deoxyspergualin on pancreatic islet xenotransplantation. 1992 Transplant. Proc. pmid:1373546
Matsuzaki T et al. Liver transplantation for diethylnitrosamine-induced hepatocellular carcinoma in rats. 1992 Transplant. Proc. pmid:1373547
Vincent SH et al. In vitro metabolism of FK-506 in rat, rabbit, and human liver microsomes: identification of a major metabolite and of cytochrome P450 3A as the major enzymes responsible for its metabolism. 1992 Arch. Biochem. Biophys. pmid:1373595
Liu J et al. Inhibition of T cell signaling by immunophilin-ligand complexes correlates with loss of calcineurin phosphatase activity. 1992 Biochemistry pmid:1373650
Adachi A et al. Immunosuppressive effect of FK506 on experimental allergic neuritis in Lewis rats: change of T cell subsets. 1992 Intern. Med. pmid:1373661
Jegasothy BV et al. Tacrolimus (FK 506)--a new therapeutic agent for severe recalcitrant psoriasis. 1992 Arch Dermatol pmid:1376102
Wiederrecht G et al. Isolation of a human cDNA encoding a 25 kDa FK-506 and rapamycin binding protein. 1992 Biochem. Biophys. Res. Commun. pmid:1376117
Bernstein L and Daviss SR Organic anxiety disorder with symptoms of akathisia in a patient treated with the immunosuppressant FK506. 1992 Gen Hosp Psychiatry pmid:1376291
Hatfield SM et al. Rapamycin and FK506 differentially inhibit mast cell cytokine production and cytokine-induced proliferation and act as reciprocal antagonists. 1992 J. Pharmacol. Exp. Ther. pmid:1376361
Ericzon BG et al. The effect of FK506 treatment on pancreaticoduodenal allotransplantation in the primate. 1992 Transplantation pmid:1376501
Tze WJ et al. FK 506--an effective immunosuppressant in achieving long-term functional islet allograft survival in diabetic rats. 1992 Transplant. Proc. pmid:1376509
Yasunami Y et al. Induction of donor-specific unresponsiveness in rat islet allografts by FK 506. 1992 Transplant. Proc. pmid:1376510
Kai N et al. A study on the timing of immunologic priming in autoimmune insulitis in NOD mice. 1992 Transplant. Proc. pmid:1376511
Hirano Y et al. The effects of FK506 and cyclosporine on the exocrine function of the rat pancreas. 1992 Transplantation pmid:1279850
Takaya S et al. Liver transplantation in positive cytotoxic crossmatch cases using FK506, high-dose steroids, and prostaglandin E1. 1992 Transplantation pmid:1279851
Partaledis JA et al. Saccharomyces cerevisiae contains a homolog of human FKBP-13, a membrane-associated FK506/rapamycin binding protein. 1992 Yeast pmid:1279908
Ozawa K et al. An appraisal of pediatric liver transplantation from living relatives. Initial clinical experiences in 20 pediatric liver transplantations from living relatives as donors. 1992 Ann. Surg. pmid:1280074
Akutsu I et al. [Inhibitory effects of cyclosporin A and FK-506 on eosinophil chemotactic factor activity in culture supernatants of mononuclear cells from asthmatics]. 1992 Arerugi pmid:1280086
Bergstrand H and Lundquist B Human basophil histamine release is differently affected by inhibitors of calmodulin, diacylglycerol kinase and peptidyl prolyl cis-trans isomerase in a secretagogue specific manner. 1992 Allergy pmid:1280915
Barry JM Immunosuppressive drugs in renal transplantation. A review of the regimens. 1992 Drugs pmid:1281071
Stiff DD et al. Metabolism of FK 506 in differentially induced rat liver microsomes. 1992 Res. Commun. Chem. Pathol. Pharmacol. pmid:1281332
Natazuka T FK506 reverses adriamycin resistance in a multidrug-resistant human leukemia cell line. 1992 Kobe J Med Sci pmid:1284834
Tocci MJ and Sigal NH Recent advances in the mechanism of action of cyclosporine and FK506. 1992 Curr. Opin. Nephrol. Hypertens. pmid:1285380
Bavandi A et al. Diet-induced dermatitis response of hairless rats to systemic treatment with cyclosporin A (Sandimmun), cyclosporin H and FK506. 1992 Exp. Dermatol. pmid:1285411
High KP and Handschumacher RE Immunity, microbial pathogenesis, and immunophilins: finding the keys, now where are the locks? 1992 Infect Agents Dis pmid:1285413
Akutsu I et al. [Inhibitory effect of inhaled FK-506 on increased bronchial responsiveness and eosinophil infiltration in the airway mucosa]. 1992 Arerugi pmid:1377905
Takaori K et al. A comparative study on immunosuppressive effects of cyclosporin A and FK 506 on peripheral blood lymphocytes in dogs. 1992 Biotherapy pmid:1377926
Murthy JN et al. Radioreceptor assay for quantifying FK-506 immunosuppressant in whole blood. 1992 Clin. Chem. pmid:1377995
Takai K et al. Effects of FK506 on rat thymic epithelial cells; immunohistochemical study. 1992 Thymus pmid:1378235
Dutz JP et al. Effects of cognate peptides on cytolytic and proliferative activities of cloned cytotoxic T lymphocytes. 1992 Int. Immunol. pmid:1378297
Takada K et al. Distribution kinetics of FK-506, a novel immunosuppressant, after intravenous administration to rats in comparison with cyclosporin A. 1992 Biopharm Drug Dispos pmid:1379839
Kahan BD Cyclosporin A, FK506, rapamycin: the use of a quantitative analytic tool to discriminate immunosuppressive drug interactions. 1992 J. Am. Soc. Nephrol. pmid:1379841
Lauerma AI et al. Inhibition of contact allergy reactions by topical FK506. 1992 Lancet pmid:1380111
Steiner JP et al. High brain densities of the immunophilin FKBP colocalized with calcineurin. 1992 Nature pmid:1380130
Aperia A et al. Calcineurin mediates alpha-adrenergic stimulation of Na+,K(+)-ATPase activity in renal tubule cells. 1992 Proc. Natl. Acad. Sci. U.S.A. pmid:1380157
Nielsen JB et al. Yeast FKBP-13 is a membrane-associated FK506-binding protein encoded by the nonessential gene FKB2. 1992 Proc. Natl. Acad. Sci. U.S.A. pmid:1380159
Calvo V et al. Interleukin 2 stimulation of p70 S6 kinase activity is inhibited by the immunosuppressant rapamycin. 1992 Proc. Natl. Acad. Sci. U.S.A. pmid:1380162
Fruman DA et al. Correlation of calcineurin phosphatase activity and programmed cell death in murine T cell hybridomas. 1992 Eur. J. Immunol. pmid:1382988
Mittrücker HW and Fleischer B Functional localization of an exocytosis-triggering G-protein in human cytotoxic T lymphocytes. 1992 Immunology pmid:1383135
Yasutomi D et al. Inhibition of programmed cell death by cyclosporin A; preferential blocking of cell death induced by signals via TCR/CD3 complex and its mode of action. 1992 Immunology pmid:1383138
Ruff VA et al. Tissue distribution and cellular localization of hsp56, an FK506-binding protein. Characterization using a highly specific polyclonal antibody. 1992 J. Biol. Chem. pmid:1383222
Wiederrecht G et al. Characterization of high molecular weight FK-506 binding activities reveals a novel FK-506-binding protein as well as a protein complex. 1992 J. Biol. Chem. pmid:1383226
Morris RE Immunopharmacology of new xenobiotic immunosuppressive molecules. 1992 Semin. Nephrol. pmid:1384096
Hendey B et al. Inhibition of neutrophil chemokinesis on vitronectin by inhibitors of calcineurin. 1992 Science pmid:1384129
Roberti I et al. Evidence that the systematic analysis of bile cytology permits monitoring of hepatic allograft rejection. 1992 Transplantation pmid:1384182
Wang SC et al. FK-506 inhibits proliferation and IL-4 messenger RNA production by a T-helper 2 cell line. 1992 J. Surg. Res. pmid:1383612
Mizuno K et al. Modulation of multidrug resistance by immunosuppressive agents: cyclosporin analogues, FK506 and mizoribine. 1992 Jan-Feb Anticancer Res. pmid:1373592
Arai S et al. The impact of FK506 on graft coronary disease of rat cardiac allograft--a comparison with cyclosporine. 1992 Jul-Aug J. Heart Lung Transplant. pmid:1379829
Fagiuoli S et al. FK 506: a new immunosuppressive agent for organ transplantation. Pharmacology, mechanism of action and clinical applications. 1992 Jul-Aug Ital J Gastroenterol pmid:1381245
Tong J et al. Effect of FK-506 and cyclosporin A on in vitro CFU-GM growth in severe aplastic anemia patients. 1992 Jul-Aug Haematologica pmid:1385279
Nazer H et al. FK 506 associated disorders in liver transplantation. 1992 May-Jun J. Gastroenterol. Hepatol. pmid:1377038
Bowman H and Lennard TW Immunosuppressive drugs. 1992 Nov 4-17 Br J Hosp Med pmid:1282440
Sattler M et al. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. 1992 Sep-Oct Drug Metab. Dispos. pmid:1385058
Lane BC et al. Evaluation of calcineurin's role in the immunosuppressive activity of FK 506, related macrolactams, and cyclosporine. 1993 Transplant. Proc. pmid:7679829
Celli S et al. Long-term survival of heart and liver xenografts with splenectomy and FK 506. 1993 Transplant. Proc. pmid:7679830
Japanese study of FK 506 on kidney transplantation: results of late phase II study. 1993 Transplant. Proc. pmid:7679831
Kobayashi M et al. Production of monoclonal antibody against recombinant human FKBP-12 and subcellular localization of FKBP-12 in human mononuclear and polymorphonuclear cells. 1993 Transplant. Proc. pmid:7679832
Randhawa PS et al. The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Clinical significance and comparison with cyclosporine. 1993 Am. J. Surg. Pathol. pmid:7680544
Xu RX et al. Heteronuclear 3D NMR studies of water bound to an FK506 binding protein/immunosuppressant complex. 1993 Biochemistry pmid:7680570
Egan DA et al. Equilibrium denaturation of recombinant human FK binding protein in urea. 1993 Biochemistry pmid:7680574
Kim YI et al. Augmentation of hepatocyte proliferation by immunosuppressant pretherapy is associated with up-regulation of malondialdehyde production. 1993 Res Exp Med (Berl) pmid:7506444
Hytiroglou P et al. FK506 versus cyclosporine as primary immunosuppressive agent for orthotopic liver allograft recipients. Histologic and immunopathologic observations. 1993 Transplantation pmid:7506452
Ishizuka J et al. Effects of FK506 and cyclosporine on dynamic insulin secretion from isolated dog pancreatic islets. 1993 Transplantation pmid:7506454
Dhar DK et al. Effective prevention of ischemic injury of the dearterialized canine liver by FK506 pretreatment. 1993 Transplantation pmid:7506456
Nakajima J [The immunosuppressive effects of FK506 on single lung allotransplantation in Japanese monkey (Macaca fuscata)]. 1993 Nihon Kyobu Geka Gakkai Zasshi pmid:7690829
Wenzel-Seifert K and Seifert R Partial inhibition of human neutrophil activation by FK-506 at supratherapeutic concentrations. 1993 Naunyn Schmiedebergs Arch. Pharmacol. pmid:7690907
Liu J FK506 and cyclosporin, molecular probes for studying intracellular signal transduction. 1993 Immunol. Today pmid:7691065
Mori T et al. FK-506: a new immunosuppressive agent, failed to reduce cerebral vasospasm after experimental subarachnoid hemorrhage. 1993 J. Vet. Med. Sci. pmid:7691190
Takada K et al. Distribution characteristics of immunosuppressants FK506 and cyclosporin A in the blood compartment. 1993 Biopharm Drug Dispos pmid:7508273
Kawauchi M et al. Prolonged survival of orthotopically transplanted heart xenograft in infant baboons. 1993 J. Thorac. Cardiovasc. Surg. pmid:7693999
Shutter LA et al. Cortical blindness and white matter lesions in a patient receiving FK506 after liver transplantation. 1993 Neurology pmid:7694189
Dawson TM et al. Immunosuppressant FK506 enhances phosphorylation of nitric oxide synthase and protects against glutamate neurotoxicity. 1993 Proc. Natl. Acad. Sci. U.S.A. pmid:7694293
Ahmed SS et al. Adrenochrome reaction implicates oxygen radicals in metabolism of cyclosporine A and FK-506 in rat and human liver microsomes. 1993 J. Pharmacol. Exp. Ther. pmid:7685382
Sewell KL Immunotherapy and other novel therapies, including biologic response modifiers, apheresis, and dietary modifications. 1993 Curr Opin Rheumatol pmid:7685614
Wagner JA et al. Failure of FK 506 to suppress the T cell-mediated immunity of mice to Listeria monocytogenes. 1993 Clin. Exp. Immunol. pmid:7685672
Pilot-Matias TJ et al. High-level synthesis of the 12-kDa human FK506-binding protein in Escherichia coli using translational coupling. 1993 Gene pmid:7685727
Murase N et al. Hamster-to-rat heart and liver xenotransplantation with FK506 plus antiproliferative drugs. 1993 Transplantation pmid:7682735
Emond JC et al. Improved results of living-related liver transplantation with routine application in a pediatric program. 1993 Transplantation pmid:7682738
Kai N et al. Prevention of insulitis and diabetes in nonobese diabetic mice by administration of FK506. 1993 Transplantation pmid:7682740
Bram RJ et al. Identification of the immunophilins capable of mediating inhibition of signal transduction by cyclosporin A and FK506: roles of calcineurin binding and cellular location. 1993 Mol. Cell. Biol. pmid:7687744
Heitman J et al. The immunosuppressant FK506 inhibits amino acid import in Saccharomyces cerevisiae. 1993 Mol. Cell. Biol. pmid:7687745
Hirakawa K et al. [The effect of perioperative portal venous inoculation with donor lymphocytes in combination with immunosuppressive agents on rat cardiac allograft survivals]. 1993 Nihon Geka Gakkai Zasshi pmid:7688065
Entani C et al. Effect of a novel immunosuppressant, FK506, on spontaneous lupus nephritis in MRL/MpJ-lpr/lpr mice. 1993 Nephron pmid:7688103
Namiki Y et al. Tautomeric phenomenon of a novel potent immunosuppressant (FK506) in solution. I. Isolation and structure determination of tautomeric compounds. 1993 J. Antibiot. pmid:7689551
Kondo T et al. [Antitumor sensitivity test, subrenal capsule assay using FK-506: preliminary report]. 1993 Nihon Geka Gakkai Zasshi pmid:7689693
Abu-Elmagd K et al. Resolution of severe pyoderma gangrenosum in a patient with streaking leukocyte factor disease after treatment with tacrolimus (FK 506). 1993 Ann. Intern. Med. pmid:7689802
Herold KC et al. Inhibition of glucose-stimulated insulin release from beta TC3 cells and rodent islets by an analog of FK506. 1993 Transplantation pmid:7678356
Holman MJ et al. FK506-associated thrombotic thrombocytopenic purpura. 1993 Transplantation pmid:7678357
Kawai M et al. Structure-activity profiles of macrolactam immunosuppressant FK-506 analogues. 1993 FEBS Lett. pmid:7678400
Van Duyne GD et al. Atomic structures of the human immunophilin FKBP-12 complexes with FK506 and rapamycin. 1993 J. Mol. Biol. pmid:7678431